Opus Genetics (IRD) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Opus Genetics (IRD) has outperformed Ovid Therapeutics (OVID) over the past year, gaining 108.9% versus a gain of 57.1%. Over five years, IRD leads with a -8.3% price change compared with -32.5% for OVID. Ovid Therapeutics is the larger company by market cap ($415.2 million vs $385.7 million), about 1.1 times the size.
Ovid Therapeutics converts more of its revenue into profit, with a net margin of -240.1% versus -349.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRD | OVID |
|---|---|---|
| Share price | $3.99 | $2.20 |
| Market cap | $385.65M | $415.21M |
| 1-day change | -2.21% | -5.98% |
| YTD return | +98.51% | +34.97% |
| 1-year return | +108.90% | +57.14% |
| 5-year return | -8.28% | -32.52% |
| EPS (TTM) | $-1.48 | $-0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $14.20M | $7.25M |
| Revenue growth (YoY) | +29.15% | +1181.27% |
| Net income (latest FY) | $-49.59M | $-17.41M |
| Operating margin | -271.90% | -585.20% |
| Net margin | -349.33% | -240.13% |
| 52-week high | $7.07 | $3.11 |
| 52-week low | $1.88 | $1.26 |
| Distance from 52-week high | -43.56% | -29.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +249.37% | +179.55% |
| Average volume | 2.56M | 1.98M |
| Shares outstanding | 96.65M | 188.73M |
| Employees | 27 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed OVID by 51.8 percentage points over the past year.
- Ovid Therapeutics is more profitable, keeping -240.1 cents of every revenue dollar as net income versus -349.3 cents for Opus Genetics.
- Ovid Therapeutics grew revenue faster in its latest fiscal year (+1181.27% vs +29.15%).
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
IRD vs OVID FAQ
Which is bigger, Opus Genetics or Ovid Therapeutics?
Ovid Therapeutics (OVID) is larger, with a market capitalization of $415.21M compared with $385.65M for Opus Genetics (IRD).
Which stock has performed better over the past year, IRD or OVID?
IRD returned +108.90% over the past 12 months, compared with +57.14% for OVID (price return, excluding dividends). Past performance does not predict future results.
Are Opus Genetics and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.